Sign in Register

Drug class

Multiple Sclerosis Agents, General

The classification "Multiple Sclerosis Agents, General" represents a broad administrative and formulary category rather than a single pharmacologic drug class defined by a shared molecular mechanism. Read more about Multiple Sclerosis Agents, General

115 drugs in this class 49 manufacturers

Related classes & indications

Antipsychotics, AtypicalCNS, pain & psychiatry · 296 prescription drugs Antidepressant Serotonin-Norepinephrine Reuptake Inh.(SNRIs)CNS, pain & psychiatry · 127 prescription drugs Relapsing Form Of Multiple SclerosisTop indication · 125 prescription drugs

Showing 1–9 of 115 drugs

Sort

KESIMPTA PEN (ofatumumab)

ANTINEOPLASTIC MONOCLONAL ANTIBODIES · RELAPSING FORM OF MULTIPLE SCLEROSIS ·+1

Novartis Pharmaceuticals

REBIF (interferon beta-1a/albumin human)

MULTIPLE SCLEROSIS AGENTS, GENERAL · RELAPSING FORM OF MULTIPLE SCLEROSIS ·+1

EMD SERONO, INC

AVONEX (interferon beta-1a)

MULTIPLE SCLEROSIS AGENTS, GENERAL · RELAPSING FORM OF MULTIPLE SCLEROSIS ·+1

BIOGEN-IDEC

GILENYA (fingolimod HCl)

MULTIPLE SCLEROSIS AGENTS, GENERAL · RELAPSING FORM OF MULTIPLE SCLEROSIS ·+1

Novartis Pharmaceuticals

COPAXONE (glatiramer acetate)

GLATIRAMER (MULTIPLE SCLEROSIS) · RELAPSING FORM OF MULTIPLE SCLEROSIS ·+1

TEVA NEUROSCIEN

AVONEX (interferon beta-1a/albumin human)

MULTIPLE SCLEROSIS AGENTS, GENERAL · RELAPSING FORM OF MULTIPLE SCLEROSIS ·+1

BIOGEN-IDEC

BETASERON (interferon beta-1b)

MULTIPLE SCLEROSIS AGENTS, GENERAL · RELAPSING FORM OF MULTIPLE SCLEROSIS ·+1

Bayer HealthCare

TYSABRI (natalizumab)

INFLAMMATORY BOWEL AGENTS · CROHN'S DISEASE ·+2

BIOGEN-IDEC

REBIF (interferon beta-1a/albumin human)

MULTIPLE SCLEROSIS AGENTS, GENERAL · RELAPSING FORM OF MULTIPLE SCLEROSIS ·+1

EMD SERONO, INC

Filter & compare in the drug finder → Opens the drug finder with Multiple Sclerosis Agents, General preselected. Add indication or manufacturer filters there.

About Multiple Sclerosis Agents, General.

The classification "Multiple Sclerosis Agents, General" represents a broad administrative and formulary category rather than a single pharmacologic drug class defined by a shared molecular mechanism.

It encompasses diverse disease-modifying therapies (DMTs) and symptomatic treatments, including interferons, glatiramer acetate, sphingosine-1-phosphate receptor modulators, fumarates, and monoclonal antibodies.

These agents work predominantly through immunomodulatory and immunosuppressive pathways to decrease central nervous system inflammation, reduce clinical relapse frequency, and slow disability progression.

Clinically, these medications are primarily indicated for treating spectrum disorders of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and progressive forms of multiple sclerosis.

ks.gov
The classification "Multiple Sclerosis Agents, General" represents a broad administrative and formulary category rather than a single pharmacologic drug class defined by a shared molecular mechanism
cms.gov
The classification "Multiple Sclerosis Agents, General" represents a broad administrative and formulary category rather than a single pharmacologic drug class defined by a shared molecular mechanism
nationalmssociety.org
It encompasses diverse disease-modifying therapies (DMTs) and symptomatic treatments, including interferons, glatiramer acetate, sphingosine-1-phosphate receptor modulators, fumarates, and monoclonal antibodies
nv.gov
It encompasses diverse disease-modifying therapies (DMTs) and symptomatic treatments, including interferons, glatiramer acetate, sphingosine-1-phosphate receptor modulators, fumarates, and monoclonal antibodies
drugs.com
It encompasses diverse disease-modifying therapies (DMTs) and symptomatic treatments, including interferons, glatiramer acetate, sphingosine-1-phosphate receptor modulators, fumarates, and monoclonal antibodies
patsnap.com
It encompasses diverse disease-modifying therapies (DMTs) and symptomatic treatments, including interferons, glatiramer acetate, sphingosine-1-phosphate receptor modulators, fumarates, and monoclonal antibodies These agents work predominantly through immunomodulatory and immunosuppressive pathways to decrease central nervous system inflammation, reduce clinical relapse frequency, and slow disability progression
nih.gov
These agents work predominantly through immunomodulatory and immunosuppressive pathways to decrease central nervous system inflammation, reduce clinical relapse frequency, and slow disability progression
fda.gov
Clinically, these medications are primarily indicated for treating spectrum disorders of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and progressive forms of multiple sclerosis
fda.gov
Clinically, these medications are primarily indicated for treating spectrum disorders of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and progressive forms of multiple sclerosis
fda.gov
Clinically, these medications are primarily indicated for treating spectrum disorders of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and progressive forms of multiple sclerosis